Substituted thioureas have been of recent interest due to appearance of this functionality in drug candidates. A some of various substituted thioureas evaluated for antituberculosis activity in addition thioureas have been shown significant anti-human immunodeficiency virus (HIV) activity. This situation is extremely important for patient infected Mycobacterium tuberculosis and HIV, if compounds have both antituberculosis and anti-HIV activity. Researches have been indicated that thiourea derivatives have been shown noteworthy antituberculosis and anti-HIV activity. The clinical studies of N-(2-(2-pyridylethyl))-N’(2-(5-bromopyridyl) thiourea (trovirdine, LY300046.HCL) have been carried out for the treatment of the AIDS. Thiourea derivative, burimamide, is also the first described H₂-receptor histamine antagonist. Mass cell LTC₄ release inhibitor activity of thiourea derivatives have been identified. N-[1-(1-naphthyl)ethyl]-N’[2-(ethyl-4-acetylthiazolyl)] thiourea and N-[1-(1R)-naphthylethyl)]-N’[2-(5-methyl-pyridyl)]thiourea were identified as the lead compounds. Thiourea derivatives were reported to show variety of biological activities like antibacterial, antifungal, antiinflammatory and antihypertensive activity. And also various of the thiourea were synthesized and evaluated for the somatotropin release-inhibiting factor receptor subclass. Receptor binding affinity 3-[3-(1H-imidazol-4-yl)ethyl]-1-[2-[N-(5-bromopyrid-2-yl)N-(3,4-dichlorobenzyl)aminopyropyl thiourea (NNC 26-9100) exhibited high selectivity for sst₄ over sst₂. The other medicinal applications were reported potent inhibitors of phosphorylation of platelet derived growth factor receptor.